CNSX:MYM

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

MYM Nutraceuticals Inc. cultivates, processes, and sells cannabis in Canada. More Details


Snowflake Analysis

Adequate balance sheet and overvalued.


Similar Companies

Share Price & News

How has MYM Nutraceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MYM is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 26% a week.

Volatility Over Time: MYM's weekly volatility has increased from 21% to 26% over the past year.


Market Performance


7 Day Return

22.2%

MYM

9.0%

CA Pharmaceuticals

0.2%

CA Market


1 Year Return

46.7%

MYM

47.4%

CA Pharmaceuticals

1.5%

CA Market

Return vs Industry: MYM matched the Canadian Pharmaceuticals industry which returned 46.7% over the past year.

Return vs Market: MYM exceeded the Canadian Market which returned 1.6% over the past year.


Shareholder returns

MYMIndustryMarket
7 Day22.2%9.0%0.2%
30 Day15.8%30.1%3.6%
90 Day120.0%76.7%13.3%
1 Year46.7%46.7%47.4%47.4%5.2%1.5%
3 Year-96.7%-96.7%-52.9%-53.6%13.1%2.3%
5 Year266.7%266.7%417.8%414.2%69.3%43.3%

Long-Term Price Volatility Vs. Market

How volatile is MYM Nutraceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is MYM Nutraceuticals undervalued compared to its fair value and its price relative to the market?

1.59x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MYM's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate MYM's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MYM is unprofitable, so we can't compare its PE Ratio to the CA Pharmaceuticals industry average.

PE vs Market: MYM is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MYM's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MYM is good value based on its PB Ratio (1.6x) compared to the CA Pharmaceuticals industry average (2.7x).


Next Steps

Future Growth

How is MYM Nutraceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

60.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as MYM Nutraceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has MYM Nutraceuticals performed over the past 5 years?

-59.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MYM is currently unprofitable.

Growing Profit Margin: MYM is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MYM is unprofitable, and losses have increased over the past 5 years at a rate of 59.4% per year.

Accelerating Growth: Unable to compare MYM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MYM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-61.1%).


Return on Equity

High ROE: MYM has a negative Return on Equity (-99.41%), as it is currently unprofitable.


Next Steps

Financial Health

How is MYM Nutraceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: MYM's short term assets (CA$4.7M) exceed its short term liabilities (CA$3.3M).

Long Term Liabilities: MYM's short term assets (CA$4.7M) exceed its long term liabilities (CA$2.8M).


Debt to Equity History and Analysis

Debt Level: MYM's debt to equity ratio (16.7%) is considered satisfactory.

Reducing Debt: MYM's debt to equity ratio has reduced from 140.1% to 16.7% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MYM has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: MYM has less than a year of cash runway if free cash flow continues to reduce at historical rates of 42.5% each year


Next Steps

Dividend

What is MYM Nutraceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MYM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MYM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MYM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MYM's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MYM's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average management tenure


CEO

Michael Wiener

0.50

Tenure

Mr. Michael Wiener is Chief Executive Officer & Director at MYM Nutraceuticals Inc. since July 31, 2020. He has been an Executive Vice President and Chief Executive Officer of 35 Oak Holdings Limited since...


Leadership Team

NamePositionTenureCompensationOwnership
Mark Forster
Chief Financial Officer0.42yrCA$733.70k0.60%
CA$ 153.9k
Robin Linden
Executive VP3.17yrsCA$191.63k0.45%
CA$ 115.7k
Michael Wiener
CEO & Director0.50yrno data5.77%
CA$ 1.5m
James Andrews
Vice President of Operations1yrno datano data
Billy Casselman
Vice President of Commercial Sales & Investor Relations1.92yrsno datano data
Fiona Orr
Legal Counsel1yrno datano data
Matthew Simms
Head of Sales1yrno datano data
Laird Choi
Executive Vice President of Corporate Services1yrno datano data
Sheryl Dhillon
Corporate Secretary0.33yrno datano data

1.0yrs

Average Tenure

Experienced Management: MYM's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Robin Linden
Executive VP3.17yrsCA$191.63k0.45%
CA$ 115.7k
Michael Wiener
CEO & Director0.50yrno data5.77%
CA$ 1.5m
Howard Steinberg
Independent Non-Executive Chairman of the Board1.42yrsCA$250.00k0.13%
CA$ 32.4k
Robert Wolf
Independent Director0.50yrno data1.16%
CA$ 300.0k
Frank Klees
Member of Advisory Board2.42yrsno datano data
Edward Tabisz
Independent Director2.67yrsno data0.012%
CA$ 3.2k

1.9yrs

Average Tenure

60yo

Average Age

Experienced Board: MYM's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 54.5%.


Top Shareholders

Company Information

MYM Nutraceuticals Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: MYM Nutraceuticals Inc.
  • Ticker: MYM
  • Exchange: CNSX
  • Founded: 2014
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$25.863m
  • Shares outstanding: 246.32m
  • Website: https://www.mym.ca

Number of Employees


Location

  • MYM Nutraceuticals Inc.
  • 409 West Pender Street
  • Suite 1500
  • Vancouver
  • British Columbia
  • V6E 2M6
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MYMCNSX (Canadian National Stock Exchange)YesCommon SharesCACADNov 2014
0MYDB (Deutsche Boerse AG)YesCommon SharesDEEURNov 2014
MYMM.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDNov 2014

Biography

MYM Nutraceuticals Inc. cultivates, processes, and sells cannabis in Canada. The company was formerly known as My Marijuana Canada Inc. and changed its name to MYM Nutraceuticals Inc. in February 2016. MYM...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/18 23:07
End of Day Share Price2021/01/18 00:00
Earnings2020/08/31
Annual Earnings2020/05/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.